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Resource utilization included surgical procedures, implants,
spectacles, visits to ophthalmologists and eye-centers, trans-
portation, and time lost by patients. Discount rates and sensi-
tivity analyses were performed. Two perspectives were
considered: Sickness Fund (SF) and Societal. RESULTS: Specta-
cle-free rates were >80% for ReSTOR® and 40% for MFIOLs.
Mean lifetime numbers of spectacles purchased were 4.2 with
ReSTOR®, 12.7 with MFIOLs, and 21.3 without PS. Early PS
avoided 0.80 late cataract surgeries per subjects. Surgical proce-
dure costs were €3292 for ReSTOR® and €2292 for other
MFIOLs, respectively. From the societal perspective, total undis-
counted costs for ReSTOR® were €5268, €7170 for other
MFIOLs, and €8492 without PS. With a 3% discount rate, these
costs were €4569, €5071 and €4244, respectively. From the SF
perspective, total undiscounted costs were €146 with ReSTOR®,
€437 with MFIOLs, and €1.688 without PS. With a 3% discount
rate, these costs were €76, €227 and €747, respectively. 
CONCLUSION: PS should decrease the undiscounted costs 
of vision care from both perspectives. For SF it is highly beneﬁ-
cial while PS remains unlisted for reimbursement. For Society,
the discounted incremental cost of avoiding spectacles at age 45
was less than €9/year. ReSTOR® improves patients’ lifestyle and
is a cost-effective alternative versus spectacles in presbyopic
patients.
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OBJECTIVE: To compare the lifetime costs and consequences of
liberating patients from spectacles, after cataract surgery, by
implanting the multifocal IOL “ReSTOR®” versus monofocal
IOLs. METHODS: A Markov model was created to follow
patient cohorts from cataract surgery until death. Prevalence
rates of patients not needing spectacles after cataract surgery
were obtained from a clinical trial. Resource utilization included
implant surgery, IOLs, spectacles, visits to ophthalmologists and
eye centers, transportation, and time lost by patients. Economic
perspectives were those of Society and Sick Funds (SF). Mortal-
ity rates were introduced into the model. Discount rates were
applied. Sensitivity analyses were performed. Patients were fol-
lowed from age 70 to 100 years. RESULTS: More than 80% of
patients implanted with ReSTOR® were spectacle-free com-
pared to about 10% with monofocal IOLs. The mean number
of spectacles purchased was 1.7 after ReSTOR® and 7.6 after
monofocal IOLs. Surgical costs were €3292 for ReSTOR® and
€2292 for monofocal IOLs. From the societal perspective, total
undiscounted cost estimates were €4384 with ReSTOR® com-
pared to €5359 with monofocal IOLs. With a 3% discount rate
these costs became €4226 and €4654, respectively. From the SF
perspective, total undiscounted cost estimates were €2350 with
ReSTOR® and €2553 with monofocal IOLs. With a 3% dis-
count these costs became €2334 and €2481, respectively. Costs
and intervals between spectacle replacements were the most sen-
sitive parameters. CONCLUSION: From both the societal and
SF perspectives, undiscounted savings achieved by liberating
patients from spectacles counterbalanced the initially higher cost
of ReSTOR®. For Society, the discounted incremental cost of
avoiding spectacles after ReSTOR® implants was less than
€13/year, and SF saved money. ReSTOR® improves patients’
lifestyle and is a cost-effective alternative versus spectacles in
patients requiring cataract surgery.
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BACKGROUND: European studies have identiﬁed primary
open angle glaucoma (POAG) as the second leading cause of
blindness, accounting for 8–10% of blindness in older people.
The objective of this study was to estimate the societal costs and
the quality of life among patients with late stage POAG.
METHODS: Charts of late stage POAG patients in France,
Germany, the UK and Denmark were reviewed and the patients
were interviewed. Costs and utility values of health related
quality of life were estimated (based on resource use multiplied
with unit costs and on EQ-5D questionnaire). RESULTS: 162
patients were included. Average level of visual acuity was 0.28
and 0.11 of the best and worst eye, respectively. Annual health
maintenance costs of late stage glaucoma patients are €830 (SD:
€445). This does not include costs of surgery and larger proce-
dures. Purchase costs of devices amount to €2045 per patient.
Most importantly, however, are costs of home care, which
average €2703 per year. With respect to the health related quality
of life the average score is 0.67 and best predictor of QoL is
visual acuity of the patients’ best eye (negatively correlated, p =
0.005). Best eye visual acuity is also negatively correlated with
health care maintenance costs (p = 0.024). With respect to home
care costs the correlation is positive but not signiﬁcant. CON-
CLUSIONS: This study shows that late stage glaucoma is asso-
ciated with considerable health care and—in particular—social
care costs (home care). It is an important ﬁnding that mainte-
nance health care costs is negatively correlated with visual acuity
(and thereby QoL). A lower visual acuity is predictive of lower
QoL.
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OBJECTIVE: To assess the cost-effectiveness of bimatoprost,
latanoprost, and travoprost monotherapy in patients with open-
angle glaucoma in Denmark, Norway, and Sweden (Scandi-
navia). METHODS: Cost-effectiveness analysis was performed
using a Markov decision-analytic health economic model with
stable and progressed glaucoma as the health states. Transition
probabilities for primary open-angle and exfoliation glaucoma
were derived from published medical literature, and information
regarding clinical practice patterns was obtained from surveys
completed by 45 ophthalmologists dispersed throughout each of
the countries. Country-speciﬁc unit costs were used for medica-
tions, clinic visits, diagnostics, and outpatient services. Quality
of life weights for various levels of visual acuity ranged from 0.50
to 0.68, and the effectiveness metric was the quality-adjusted life
year (QALY). A 5-year time horizon was adopted, analyses were
from a payer perspective, and costs were discounted at 3% per
year. RESULTS: Effectiveness (years till progression) was within
a narrow range (3.2048 to 3.2613 QALYs) across all products
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in each country. Latanoprost was 3% less expensive than
bimatoprost and travoprost in Norway and Sweden, and the
costs of the 3 agents were within 1% of each other in Denmark.
Latanoprost dominated (i.e., was more effective and less expen-
sive than) bimatoprost and travoprost in Norway and Sweden.
In Denmark, bimatoprost dominated travoprost. Although
bimatoprost was slightly less expensive than latanoprost in
Denmark (DKK 28,700 vs 29,000, respectively), latanoprost was
more effective yielding an incremental cost-effectiveness ratio of
DKK 47,871. CONCLUSIONS: In Scandinavia, latanoprost was
more cost-effective than other available prostaglandin analogues
over a 5-year period.
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OBJECTIVE: To assess the relative cost-effectiveness of
monotherapy with latanoprost or timolol in the treatment of
open-angle glaucoma in Denmark, Norway, Sweden (Scandi-
navia), and the UK (UK). METHODS: Cost-effectiveness analy-
sis was performed using a Markov model. The health states were
stable and progressed glaucoma. Transition probabilities for
primary open-angle and exfoliation glaucoma were derived from
the medical literature, and data concerning practice patterns
were obtained from surveys completed by 54 ophthalmologists
geographically dispersed throughout each of the countries.
Country-speciﬁc unit costs were assigned for medications,
patient visits, diagnostics, and therapeutic procedures. Quality
of life weights for various levels of visual acuity ranged from 0.50
to 0.68. A payer perspective with a 5-year time horizon was
adopted and costs were discounted at 3% for Scandinavia or
3.5% for the UK per year. RESULTS: Latanoprost was less
expensive than timolol, ranging from 5.4% to 6.7% less in Scan-
dinavia and by 2.1% less in the UK. The range of effectiveness
(years to progression of glaucoma) between treatment cohorts
was narrow, from 0.003 to 0.01, which may have reﬂected the
fact that the design assumed that physicians control most
patients’ glaucoma over 5 years by adding or changing therapy.
Incremental cost-effectiveness ratios for latanoprost versus
timolol were DKK 447,857 in Denmark, NOK 457,212 in
Norway, SEK 1,251,126 in Sweden, and GBP 6087 in the UK.
CONCLUSIONS: Over a 5-year period, latanoprost monother-
apy is as cost-effective as traditional timolol generics in Scandi-
navia and the UK.
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OBJECTIVES: To estimate the cost-effectiveness of pegaptanib
versus best supportive care for age-related macular degeneration
(ARMD) in the UK and to evaluate the impact of patient char-
acteristics. METHODS: A 10-year Markov model was con-
structed composed of 13 health states, 12 visual acuity (VA)
states deﬁned by individual Snellen lines and death. Time-
dependent transition probabilities for the loss and gain of Snellen
lines were derived from parametric survival models ﬁtted to
patient-level data from the VISION trial. Survival models were
ﬁtted with treatment group and baseline Snellen score as covari-
ates, and other models were ﬁtted with the addition of age,
gender, and lesion type or lesion size. Mortality rates were
adjusted for the age and gender of the model population. Utility
weights elicited using a choice-based method were derived from
the published literature. Resource use estimates were developed
by structured interview of three consultant ophthalmologists.
Other model parameters were obtained from the published lit-
erature; unit costs were obtained from national sources (cost year
2005). Uncertainty was explored by probabilistic and univariate
sensitivity analysis. RESULTS: In the base-case analysis, treat-
ment was targeted to patients with VA of 20/40 to 20/320 and
was discontinued if VA fell below 20/320 or by 6 or more lines.
The incremental cost per quality adjusted life year gained
(IC/QALY) was estimated as £8023 [upper 95% CI: £20,641].
Age had the greatest impact [age <75: £2033/QALY; age ≥75:
£11,657/QALY]. Pre-treatment VA was also important [20/40 to
20/320: £8023/QALY; 20/40 to 20/200: £6664/QALY]. Gender,
lesion type, and lesion size had little effect on the IC/QALY [all
estimates were between £7000 and £9000/QALY]. CONCLU-
SIONS: Pegaptanib treatment is expected to be cost-effective
across all groups studied, and marginally more cost-effective in
younger patients and those with better pre-treatment VA.
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OBJECTIVES: To determine the impact of differences in 
care and services provided to the visually impaired in the UK
(UK) and the United States (US) on the cost-effectiveness of
pegaptanib in age-related macular degeneration (ARMD).
MEHTODS: A Markov model was used to model the visual
acuity of a cohort of ARMD patients over a period of 10 years.
Country-speciﬁc data for the US and UK included mortality
rates, treatment-related costs, adverse event treatment patterns,
costs associated with excess cases of depression and injury, and
services provided to the visually impaired. In the UK, these con-
sisted of visual aids and rehabilitation, community and residen-
tial care, and social security beneﬁts. In the US, these included
all Medicare costs including skilled nursing facility and nursing
home care. Social security beneﬁts have not been quantiﬁed in
the US and could not be included. RESULTS: The incremental
beneﬁt of pegaptanib was slightly higher in the US than the UK
due to the slightly greater life expectancy (incremental quality-
adjusted life year [QALY] estimates were 0.302 and 0.297,
respectively). The average per patient cost associated with the
provision of services to those with visual impairment was similar
when social security beneﬁts were excluded but substantially
lower in the US than the UK when they were included ($24,815
and GBP 25,014 [∼$46,326] per patient receiving standard care,
respectively). This resulted in higher incremental cost/QALY 
estimates in the US than the UK ($37,607 and GBP 8023
[∼$14,842], respectively). CONCLUSION: Pegaptanib is
expected to be cost-effective at recognized thresholds in both
health care systems, despite differences in the provision of health
and personal care. Cost-effectiveness in the US may be underes-
timated due to the lack of information on the cost of social secu-
rity beneﬁts for the visually impaired.
